PDF herunterladen
Zeitschrift für Orthomolekulare Medizin 2013; 11(3): 6-11
DOI: 10.1055/s-0033-1350781
Wissen
Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Abschied von der Cholesterin-Hypothese und den Statinen

Hans-Peter Friedrichsen
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. Oktober 2013 (online)

    Lizenzen und Reprints

Zusammenfassung

Bis heute konnte nicht bewiesen werden, dass ein hoher Cholesterinspiegel verantwortlich ist für Arteriosklerose und Herzinfarkt. Demgegenüber haben Studien zufolge Ernährung und sportliche Aktivität einen größeren Einfluss auf das Risiko für Herz-Kreislauf-Erkrankungen. Dennoch ist die medikamentöse Cholesterinsenkung durch Statine seit Jahren gängige medizinische Praxis, obwohl diese vielfältige Nebenwirkungen haben bis hin zu erhöhten Tumorraten.

Schlüsselwörter

Cholesterin - Herz-Kreislauf-Krankheiten - Herzinfarkt - Todesrate - LDL-Cholesterin - Mittelmeerkost - Sport - Absolute Risikoreduktion (ARR) - Statine
 

  • Literatur

  • 1 Yerushalmy J, Hilleboe HE. Fat in the diet and mortality from heart disease. The New York State Journal of Medicine 1957; 57: 2343-2354
    Google Scholar
  • 2 Anderson KM et al. Cholesterol and mortality. 30 years follow-up from the Framingham study. JAMA 1987; 257: 2176-2180
    CrossrefGoogle Scholar
  • 3 MRFIT Research Group. . JAMA 1982; 248: 1465-1477
    Crossref
  • 4 Werkö L. Analysis of the MRFIT screenees. J Intern Med 1995; 237: 507-518
    CrossrefGoogle Scholar
  • 5 WHO report 2011.
    Google Scholar
  • 6 OECD Statistics 2011.
    Google Scholar
  • 7 Carroll MD. Trends in Serum Lipids and Lipoproteins in Adults 1960–2002. JAMA 2005; 294: 1773-1781
    CrossrefGoogle Scholar
  • 8 Lande KR, Sperry WM. Human atherosclerosis in relation to the cholesterol content of the blood serum. Archives of Pathology 1936; 22: 301-312
    Google Scholar
  • 9 Mathur KS. Serum Cholesterol and Atherosclerosis in Man. Circulation 1961; 23: 847-852
    CrossrefGoogle Scholar
  • 10 Paterson JC. Serum lipid levels and the severity of coronary and cerebral atherosclerosis in adequately nourished men, 60–69 years of age. Circulation 1963; 27: 229-236
    CrossrefGoogle Scholar
  • 11 Sachdeva A. Lipid levels in patients hospitalized with coronary artery disease. Am Heart J 2009; 157: 111-117
    CrossrefGoogle Scholar
  • 12 Hoevenaar-Blom MP. EPIC-NL cohort study. PLoS One 2012; 9: 1-7
    Google Scholar
  • 13 Hoevenaar-Blom MP. Cycling and sports, but not walking, are associated with 10-year cardiovascular disease incidence: the MORGEN Study. Eur J Cardiovasc Prev Rehabil 2011; 18: 41-47
    Google Scholar
  • 14 The Lipid Research CPPT Trail results I. JAMA 1984; 251: 351-364
    CrossrefGoogle Scholar
  • 15 Walley T. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 199–72003. Br J Clin Pharmacol 2005; 60: 543-551
    CrossrefGoogle Scholar
  • 16 Baigent C. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
    CrossrefGoogle Scholar
  • 17 Kausik KR. Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants. Arch Intern Med 2010; 170 (12) 1024-1031
    CrossrefGoogle Scholar
  • 18 Jenkins D. Effects of a Dietary Portfolio of Cholesterol-Lowering Foods versus Lovastatin on Serum Lipids and CRP. JAMA 2003; 290: 502-510
    CrossrefGoogle Scholar
  • 19 Goldstein MR et al. Do statins prevent or promote cancer?. Current Oncology 2008; 15: 76-77
    Google Scholar
  • 20 Charach G. Baseline low density lipoprotein cholesterol levels and outcome in patients with heart failure. Am J Card 2010; 105: 100-104
    CrossrefGoogle Scholar
  • 21 Molyneux S et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 2008; 18: 1435-1441
    Google Scholar
  • 22 Alehagen U et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and Coenzyme Q10 supplementation – KISEL 10 Study. Int J Cardiol 2012; Epub ahead of print
    Google Scholar
  • 23 Alsheikh-Ali AA et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes rhabdomyolysis and cancer. J Am Coll Cardiol 2007; 50: 409-418
    CrossrefGoogle Scholar